{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wagstaff KM"],"funding":["Leona M. and Harry B. Helmsley Charitable Trust"],"pagination":["1205"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12473430"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(9)"],"pubmed_abstract":["<b>Background:</b> The efficacy of a single oral dose of Ivermectin as prophylaxis for SARS-CoV-2 is uncertain. This trial sought to evaluate the effectiveness of a single oral low dose of Ivermectin to prevent SARS-CoV-2 infection or reduce symptoms if infection did occur. <b>Methods:</b> Asymptomatic community-dwelling adults were enrolled in this study within 72 h of close contact with a case of SARS-CoV-2. Participants were randomised, stratified by vaccination status and exposure site, to a single oral 200 µg/kg dose of Ivermectin or placebo. The primary outcome was conversion to a positive polymerase chain reaction (PCR) or rapid antigen test (RAT) for SARS-CoV-2 within 14 days of close contact. Secondary outcomes were restricted to those who met the primary outcome. They included th"],"journal":["Pharmaceutics"],"pubmed_title":["A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2."],"pmcid":["PMC12473430"],"funding_grant_id":["N/A"],"pubmed_authors":["Herschtal A","Rajter JC","Kanagalingam A","Stein MS","Smileski A","Jans DA","Sallaberger M","Rajter JJ","Wagstaff KM"],"additional_accession":[]},"is_claimable":false,"name":"A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2.","description":"<b>Background:</b> The efficacy of a single oral dose of Ivermectin as prophylaxis for SARS-CoV-2 is uncertain. This trial sought to evaluate the effectiveness of a single oral low dose of Ivermectin to prevent SARS-CoV-2 infection or reduce symptoms if infection did occur. <b>Methods:</b> Asymptomatic community-dwelling adults were enrolled in this study within 72 h of close contact with a case of SARS-CoV-2. Participants were randomised, stratified by vaccination status and exposure site, to a single oral 200 µg/kg dose of Ivermectin or placebo. The primary outcome was conversion to a positive polymerase chain reaction (PCR) or rapid antigen test (RAT) for SARS-CoV-2 within 14 days of close contact. Secondary outcomes were restricted to those who met the primary outcome. They included th","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-05T03:13:16.516Z","creation":"2026-07-05T03:11:54.122Z"},"accession":"S-EPMC12473430","cross_references":{"pubmed":["41012540"],"doi":["10.3390/pharmaceutics17091205"]}}